

LAP3 Rec'd PCT/PTO 05 MAY 2006 PCT

PATENT

Attorney Docket No.: PP19817.002



I hereby certify that this paper is being deposited with the U.S. Patent and Trademark Office as first class mail in an envelope addressed: MAIL STOP Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on May 2, 2006.

Gyne Riser

Date

05/02/06

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. National Phase of:

International Application No.: PCT/US2004/025914

International Filing Date: 12 August 2004

Applicant: Feng Xu

For: INACTIVATED HOST CELL DELIVERY OF POLYNUCLEOTIDES
ENCODING IMMUNOGENS

INFORMATION DISCLOSURE STATEMENT

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on Form PTO/SB/08, submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

This Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the patent application.
- ☐ within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.
- ☒ **before** the mailing date of a first Office Action on the merits.

- ☐ **after** the mailing date of a first Office Action on the merits, but before the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, and accordingly is accompanied by:
- ☐ the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);
- or**
- ☐ the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or
- ☒ No fee is owed by the applicant(s).
- ☐ In accordance with 37 C.F.R. § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p), is attached.
- ☐ **after** the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), (see "Statement," and "Fees" below).
- ☒ Copies of the references listed on the attached Form PTO/SB/08, are enclosed.

EXCEPT THAT:

- ☐ In view of the voluminous nature of reference @@, and the likelihood that this reference is available to the Examiner, copies are not enclosed herewith.
- ☐ In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached Form PTO/SB/08 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.

- ☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Statement under 37 C.F.R. § 1.97(e)

- ☐ The undersigned attorney hereby states that the references contained in the Information Disclosure Statement were cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement. A copy of the communication (International Search Report) is enclosed.

Fees

- ☒ No Fee is owed by the applicant(s).
- ☐ The Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.


Method of Payment of Fees

- ☐ Attached is a check in the amount of \$180.00. This form is submitted in duplicate.
- ☐ Charge Deposit Account No. 03-1664 in the amount of \$180.00. This form is submitted in duplicate.
- ☒ Please charge any deficiency or credit any overpayment to Deposit Account 03-1664.
- ☐ No fee or Statement is required under 37 C.F.R. § 1.97(b).

Respectfully submitted,

Dated: May 2, 2006

BY:



Helen Lee

Registration No. 39,270

CHIRON CORPORATION
Intellectual Property – R440
P.O. Box 8097
Emeryville, CA 94662-8097
Telephone: (510) 923-2192



THE UNITED STATES PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT
PTO/SB/08 (MODIFIED)

SHEET 1 OF 1

ATTORNEY DOCKET NO.

PP019817.0003

APPLICATION NO. (International)

PCT/US2004/025914

FIRST NAMED INVENTOR

Feng Xu

EXAMINER

Unassigned

FILING DATE (International)

August 12, 2004

CONFIRMATION NO.

GROUP ART UNIT

Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER	ISSUE DATE/ PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	A1			
	A2			
	A3			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER	PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
	B1					
	B2					
	B3					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

EXAMINE R INITIAL	REF. NO.	DESCRIPTION
	C1	JAFFE et al., "Considerations for the Clinical Development of Cytokine Gene-Transduced Tumor Cell Vaccines" <i>Methods: A Companion to Methods in Enzymology</i> (1997) 12:143-153
	C2	KOJIMA et al., "Granulocyte-Macrophage Colony-Stimulating Factor Gene-Transduced Tumor Cells Combined with Tumor-Derived gp96 Inhibit Tumor Growth in Mice", <i>Human Gene Therapy</i> (2003) 14:715-728
	C3	TJOA et al., "Progress in Active Specific Immunotherapy of Prostate Cancer", <i>Seminars in Surgical Oncology</i> (2000) 18:80-87
	C4	ZHAN et al., "Control of IL-12 and IFN-Gamma Production in Response to Live or Dead Bacteria by TNF and Other Factors", <i>J. Immunology</i> , (1988) 161:1447-1453
	C5	
	C6	
	C7	
	C8	
	C9	
	C10	

EXAMINER'S SIGNATURE

DATE CONSIDERED